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The objective of this research was to design a new colon-targeted drug delivery system based on chitosan. 
The properties of the films were studied to obtain useful information about the possible applications of 
composite films. The composite films were used in a bilayer system to investigate their feasibility as 
coating materials. Tensile strength, swelling degree, solubility, biodegradation degree, Fourier transform 
infrared spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Scanning electron microscope 
(SEM) investigations showed that the composite film was formed when chitosan and gelatin were jointly 
reacted jointly. The results showed that a 6:4 blend ratio was the optimal chitosan/gelatin blend ratio. 
In vitro drug release results indicated that the Eudragit- and chitosan/gelatin-bilayer coating system 
prevented drug release in simulated intestinal fluid (SIF) and simulated gastric fluid (SGF). However, 
the drug release from a bilayer-coated tablet in SCF increased over time, and the drug was almost 
completely released after 24 h. Overall, colon-targeted drug delivery was achieved by using a chitosan/
gelatin complex film and a multilayer coating system.
Uniterms: Chitosan/gelatin complex film/drugs coating. Chitosan/multilayer coating system/drugs 
coating. Drugs/delivery system/colon-targeted. Tablets/bilayer-coated.
O objetivo desta pesquisa foi planejar um novo sistema de liberação de fármacos direcionado ao cólon, 
utilizando quitosana. Estudaram-se as propriedades dos filmes a fim de obter informações úteis sobre a 
aplicação desses filmes compósitos. Utilizaram-se os filmes compósitos em sistema de bicamada para 
investigar a sua viabilidade como materiais de revestimento. Estudos de resistência à tração, grau de 
intumescimento, solubilidade, grau de biodegradação, no infravermelho por transformada de Fourier 
(FTIR), de calorimetria diferencial de varredura (DSC) e de microscopia eletrônica de varredura (SEM) 
mostraram que o filme compósito se formou quando a quitosana e a gelatina reagiram entre si. Os 
resultados mostraram que a mistura de proporção ótima foi de 6:4 de quitosana:gelatina. Resultados 
da liberação do fármaco in vitro indicaram que o sistema de revestimento de Eudragit e bicamada de 
quitosana/gelatina impediu a liberação de fármaco em fluido intestinal simulado (SIF) e em fluido 
gástrico simulado (SGF). Entretanto, a liberação de fármaco do comprimido revestido em bicamada no 
SCF aumentou ao longo do tempo e o fármaco foi quase completamente liberado após 24 h. Em geral, 
se obteve a forma de liberação dirigida ao cólon, utilizando filme complexo de quitosana/gelatina e 
sistema de revestimento multicamada.
Unitermos: Quitosana/filme de complexo de gelatina. Quitosana/sistema multicamadas de revestimento/
revestimento de fármacos. Fármacos/sistema de liberação/dirigido ao cólon. Comprimidos/revestidos 
com bicamada.
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INTRODUCTION
Colon-targeted drug delivery systems have been 
increasing interest for treating colonic diseases such as 
Crohn’s disease, irritable bowel syndrome, and ulcerative 
colitis (Cao, Fu, He, 2007; Chourasia, Jain, 2004; Jain, 
Jain, 2008; Luo et al., 2011). Colon-targeted drug delivery 
increases efficacy and reduces side effects by delivering 
high drug concentrations topically at the colonic disease 
site. An ideal colon-specific drug delivery system should 
release most of the drug locally into the colon, and not into 
the stomach or small intestine (Rubinstein, 1995). Several 
strategies are currently being investigated for colon-specific 
delivery, including prodrugs (Dhaneshwar et al., 2007) 
and pH-sensitive (Yin et al., 2008; Vaghani, Patel, Satish, 
2012), time-dependent (Fude et al., 2007), and microflora-
activated systems (Dev, Bali, Pathak, 2011; Yang, 2008).
The pH of the gastrointestinal tract gradually 
increases as one moves down the gastrointestinal tract 
from the stomach (pH 1.5–3) to the terminal ileum (pH 
7–8) (Gupta, Beckert, Price, 2001). pH-sensitive delivery 
systems takes advantage of polymeric materials that 
are insoluble in the low pH environment of the upper 
gastrointestinal tract, but dissolve at the higher, near 
neutral pH of the distal gut. Microflora-activated delivery 
systems are preferable and promising (Fan et al., 2009). 
The human colon is a dynamic and ecologically diverse 
system consisting of over 400 distinct bacterial species 
(Cummings, Macfarlane, 1991) that secrete a variety 
of enzymes (Guarner, Malagelada, 2003). The primary 
sources of nutrition for these bacteria are non-starch 
polysaccharides which are fermented during their transit 
through the colon and which are negligibly broken down 
in the stomach and small intestine (Englyst, Cummings, 
1985). Currently, natural polysaccharides are extensively 
used for the development of solid dosage forms for the 
delivery of drugs to the colon (Nath, Nath, 2013).
However, it was reported that a colon-specific 
delivery system which is based only on pH-sensitive 
(Gupta, Beckert, Price, 2001) or microflora-activated 
systems have been reported as unreliable due to the 
inherent variability in pH or water swelling from the 
gastrointestinal tract. Fortunately, a bilayer system would 
serve as a unique drug delivery device that is compatible 
with conventional manufacturing methods. Similarly, 
multi-layered tablets have been developed to control drug 
delivery using a predefined release profile for different 
active ingredients. Therefore, we intend to design a new 
drug delivery system by a combining pH-sensitive system 
with microflora-activated system.
Polysaccharides, which are metabolized by the 
colonic flora, have gained widely attention as potential 
colon targeting carriers for their non-toxic, hydrophilic, 
gel-forming, biodegradable, inexpensive, and abundant 
properties and they are available in various grades of varying 
properties. Chitosan, which is a high molecular weight 
natural polysaccharide, is completely biodegradable, non-
toxic, low-cost, and has favorable gelation characteristics 
(Singla, Chawla, 2001). Chitosan cannot be digested 
in the upper gastrointestinal tract by human digestive 
enzymes (Bhattarai, Gunn, Zhang, 2010; Park et al., 2010). 
However, chitosan is prone to glycosidic hydrolysis by 
microbial enzymes in the colon (Chourasia, Jain, 2003; 
McConnell, Murdan, Basit, 2008; Muzzarelli, 2011). 
Furthermore, chitosan has been applied in colon-targeted 
drug delivery systems in several forms such as capsules 
(Tozaki, et al., 2002), matrices (Zambito, Di Colo, 2003), 
hydrogels (Zhang, Alsarra, Neau, 2002) and microspheres 
(Lorenzo-Lamosa et al., 1998). Therefore, the potential 
for chitosan to be used as a coating material is obvious. 
However, chitosan dissolves in the acidic solutions, i.e., 
a factor that would limit the applications of chitosan in 
colon-targeted drug delivery. Gelatin is a soluble protein 
compound obtained by partially hydrolyzing collagen. It 
has a number of applications in the biomedical field, such 
as in tissue engineering, wound dressing, drug delivery 
and gene therapy (Mano et al., 2007). Furthermore, gelatin 
films, which are thin, flexible and transparent biodegradable 
materials, are available for engineering food, packaging, 
drug delivery and other applications (Bergo, Sobral, 2007). 
Unfortunately, gelatin exhibits poor mechanical properties, 
limiting its possible applications. Blending is an easy way to 
improve the properties of polymer materials. Based on the 
above, a chitosan/gelatin complex film was prepared as an 
inner coat. Eudragit® L100, anionic copolymers, dissociates 
above pH 6.0 and was used as the outer coat.
The objective of this study was to develop a multi-
unit delivery system of a model drug so that the majority of 
the drug release occurs in the colon in a sustained-release 
fashion. A schematic of the delivery system is shown 
in Figure 1. Hydrocortisone is more extensively used 
as a corticosteroid to cure inflammatory bowel disease. 
Hydrocortisone was used as a model drug in this study. 
Tablets were chosen for development because they are 
more economical and easier to industrialize.
MATERIAL AND METHODS
Material
Hydrocortisone was purchased from Jinjin 
Pharmaceutical Co. Ltd. (Tianjin, China). The following 
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excipients and chemicals were purchased from commercial 
sources and used as received: chitosan (deacetylation 
degree 96%, Haidebei Co. Ltd., Shandong, China), 
microcrystalline cellulose (MCC, Huzhou Zhanwang 
Medical Company, Huzhou, China), Eudragit® L100 
(Röhm Pharm, Darmstadt, Germany), triethylcitrate 
(TEC, Johnson Matthey company, USA), polyethylene 
glycol (PEG) 6000 (Pudong Chemical Co., Shanghai, 
China), talc and magnesium stearate (Shanghai Yunhong 
Pharmaceutical Excipients & Technology Co. Ltd., 
Shanghai, China), lactose and gelatin (Beijing Aoboxing 
Biotechnology, Beijing, China), and pepsin, lipase 
and pectinase (Beijing Kebio Biotechnology, Beijing, 
China). The solvents were reagent grade; double distilled 
deionized water was used in all experiments.
Film preparation
Gelatin was dissolved in ultra-pure water, and 
chitosan was dissolved in a 2% acetic acid solution. The 
gelatin and chitosan solutions were mixed at different 
weight ratios (Table I) and PEG6000 was added as a 
plasticizer. Subsequently, the mixed solution was stirred 
for 15 min at room temperature. In this reaction, the gelatin 
and the chitosan array formed a complex. Subsequently, 
the mixtures were cast onto silanized glass Petri dishes and 
dried at room temperature for 5-7 days. After drying, the 
gelatin/chitosan films were removed from the Petri dishes 
and stored in desiccators at room temperature.
Preparation of the simulated gastric/intestinal 
fluid
Preparation of the simulated gastric/intestinal fluid 
with enzyme
A simulated gastric fluid (SGF) was prepared 
comprising an aqueous solution containing 12,000 U/L 
pepsin adjusted to pH 1.5 using 0.1 M HCl. A simulated 
intestinal fluid (SIF) was prepared comprising an 8400 
U/L lipase solution in a phosphate buffer (pH 7.4). A 
simulated colonic fluid (SCF) was prepared comprising 
a 6 g/L pectinase solution in a phosphate buffer (pH 6.8).
Preparation of the simulated colonic fluid with rat 
colonic medium (RCM)
The extracellular enzymes released from the 
microflora in rat colonic contents had more profound 
degradation effects on chitosan than their membrane 
enzymes (Zhang, Alsarra, Neau, 2002). Therefore, 
rat colonic medium was prepared. Male Wistar rats 
(200-300 g) were lightly anesthetized using ether, and 
sacrificed by decapitation. Their caeca were exteriorized, 
cauterized at both ends (2.0 cm apart), cut loose, and 
immediately removed from the rat body. The formed cecal 
bag was opened, and its contents were weighed, pooled, 
and suspended in two volumes of cold bicarbonate-
buffered saline to give a final cecal dilution of 33% 
(w/v). The suspension was filtered through a 400 mesh 
grit twice to remove any debris. The supernatant was 
then centrifuged at 15,000 x g for 30 min to obtain a 
FIGURE 1 - Bilayer coated tablet. Bilayer coated tablet was prepared in this study (A); shematic of the bilayer coated tablet delivery 
system (not to scale) (B).
TABLE I - Formulation design of film
Formulation 
No. (FN) Composition Weight Rate
1 Gelatin/chitosan/PEG 10:0: 1
2 Gelatin/chitosan/PEG 9:1:1
3 Gelatin/chitosan/PEG 8:2:1
4 Gelatin/chitosan/PEG 7:3:1
5 Gelatin/chitosan/PEG 6:4:1
6 Gelatin/chitosan/PEG 5:5:1
7 Gelatin/chitosan/PEG 4:6:1
8 Gelatin/chitosan/PEG 3:7:1
9 Gelatin/chitosan/PEG 2:8:1
10 Gelatin/chitosan/PEG 1:9:1
11 Gelatin/chitosan/PEG 0:10:1
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clear supernatant containing the extracellular enzymes 
(Zhang, Alsarra, Neau, 2002). The animal study protocol 
was approved by the Animal Care and Use Committee of 
Harbin Medical University.
Film characteristics
Appearance
The surface conditions and color of the gelatin/
chitosan films were observed.
Thickness
The thickness of the gelatin/chitosan films was 
determined with a micrometer, and the average value of 
10 measurements taken at random points was reported.
Tensile strength measurement
The gelatin/chitosan films were cut into rectangular 
samples. Four tests were performed with each film at 
room temperature using an electronic universal testing 
machine BLD 200S (Jinan, China). The characteristic 
parameters of the rectangular samples included a 40-mm 
gauge length and a 10-mm width. Average values 
from at least three measurements were reported. The 
tensile strength (TS) was calculated using the following 
expression:
 δ=P/(b×d) (Equation 1)
where δ is the tensile strength, P is the maximal tension 
needed to break the film, b is the width of the film and d 
is the thickness of the film.
Swelling of film
The  deg ree  o f  swe l l i ng  was  de t e rmined 
gravimetrically. Films 20 mm long and 20 mm wide were 
put into SGF, SIF and SCF without enzymes to swell at the 
experimental temperature. The samples were removed at 
regular intervals from the buffers, blotted with filter paper, 
weighed and replaced in the same immersion bath. This 
process was repeated until a swelling equilibrium was 
reached. The swelling degree was defined as the weight of 
water imbibed by the sample per unit weight of film. Each 
film was analyzed three times. The equilibrium swelling 
degree Q∞ was calculated in grams of water per gram of 
film using the following expression:
 Q∞ (%) = (m∞−m0)×100/m0 (Equation 2)
where m0 is the initial weight of the dried film, and m∞ is 
the weight of film at swelling equilibrium.
Solubility of film
Dried films (n = 3) were weighed (W1) and immersed 
in SGF, SIF and SCF without enzyme for 24 h, dried in 
vacuo overnight, and weighed again (W2). The solubility 
of each sample was determined three times. Solubility (S) 
was calculated using Equation (3):
 S (%) = (W1–W2)×100/W1 (Equation 3)
Fourier transform infrared spectroscopy (FTIR)
The films were cut into small pieces and KBr discs 
were prepared. Infrared spectra were recorded on an 8400S 
FTIR spectrometer (Shimadzu, Japan) in the 4000–400 
cm−1 region.
Differential Scanning Calorimetry (DSC)
DSC assays of gelatin/chitosan/PEG mixtures and 
gelatin/chitosan films were performed by using a DZ3335 
DSC (Nanjingdazhan, China) instrument. A sample (5 mg) 
was scanned in an aluminum pan over a temperature range 
between 35 °C to 340 °C under nitrogen at a scanning rate 
of 5 °C/min. All scans were performed in triplicate.
Scanning electron microscope (SEM) analysis
Surface morphologies were examined by SEM 
using a S3400N scanning microscope from Hitachi Ltd. 
Co. (Tokyo, Japan) at an accelerating voltage of 15 kV. 
Samples were mounted on metal stubs and coated with 
gold by ion sputtering instrument E-1010.
Characterization of biodegradation 
The gelatin/chitosan films with thicknesses 
averaging 0.6-0.8 mm were cut into 2 cm × 2 cm pieces. 
The film samples were degraded in 20 ml SGF (2 h), SIF 
(24 h), SCF (24 h) or RCM (24 h). Each sample was tested 
three times. The degradation degree (Dt) at time t was 
calculated using the following expression: 
 Dt = (mt − m0)/m0  (Equation 4)
where m0 is the initial weight of the dried film (at t = 0), 
and mt is the weight after a time t.
Preparation and evaluation of colon-targeted 
tablets
Core Tablet Preparation
The formulation of prototypical core tablets 
containing 10 mg hydrocortisone were prepared using 
a wet granulation technique. The tablets contained 
46% MCC, 46% lactose, 2% PVPP and 1% magnesium 
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stearate. The drug and excipients were mixed. The dry 
blend was granulated with 3% aqueous PVPK30 solution 
as the binding solution, passed through a no. 16 mesh, 
and dried at 55 °C on a tray drier. The dried granules were 
passed through a no. 20 mesh before they were blended 
with 1.0% (w/w) magnesium stearate and compressed 
using an 8-mm punch on a single punch tablet press 
(DP30A, Beijing Gylongli Sci. & Tech. Co., Ltd., China). 
Core tablets were evaluated based on friability, hardness 
and disintegration.
Preparation of Coating Tablets
Three layers of polymeric coatings were applied 
to all core tablets in the following order: HPMC, gelatin/
chitosan and Eudragit L100. The HPMC coat formulation 
was prepared by dissolving 2% (w/v) HPMC in 80% 
ethanol HPMC, the gelatin/chitosan coat formulation was 
gelatin (2%, w/v), chitosan (3%, w/v), PEG (0.5%, w/v), 
and 3% talc (3%, w/v) in 2% acetic acid solution, and the 
Eudragit L100 coat formulation was Eudragit L100 (6%, 
w/v), triethyl citrate (1%, w/v), and talc (3%, w/v) in an 
ethyl alcohol/water mixture (96/4). The coating weight 
gains for the HPMC, Eudragit L100 and gelatin/chitosan 
formulations were 2%, 4% and 20%, respectively.
In Vitro Dissolution Testing
Hydrocortisone release profiles from uncoated, 
gelatin/chitosan-coated, Eudragit-coated and bilayer-
coated tablets were assessed by three-step dissolution 
experiments (Liu et al., 2007), which were carried out 
in RC-6 dissolution tester (Tian Jin Optical Instrument 
Factory, China) to simulate the GIT under physiological 
conditions (250 mL per vessel): 2 h in SGF, 4 h in SIF 
and finally, 24 h in SCF. The stirring rates in SGF, SIF 
and SCF were 20, 20, and 5 rpm, respectively, and the 
temperature was maintained at 37 °C. Aliquots of the 
dissolution medium were withdrawn at predetermined 
times and replaced with the same volume of corresponding 
release medium to maintain a consistent volume. Each 
test was performed in triplicate and the release of 
hydrocortisone was monitored at 243 nm (UV 2000 
UV-vis spectrophotometer).
Stability studies
The bilayer-coated tablets were stored in a high-
density polyethylene plastic bottle with silica gel. A 
stability study of the bilayer-coated tablet was carried 
out according to ICH guidelines at 40 ± 2 °C/75% ± 5% 
RH. Physical attributes of the tablets, i.e., appearance, 
percentage drug content and dissolution profiles were 
tested over a period of 6 months.
Data analysis
The Rank Sum Ratio (RSR) method was used to 
evaluate the effect of the formulation composition on films 
using seven indices: tensile strength (TS), swelling degrees 
(Q) in SIF and SCF without enzyme, solubility (S) in SIF 
and SCF without enzyme, and biodegradation degree (D) 
in SIF and in SCF. High TS, Q in SCF without enzyme 
(QC), S in SCF without enzyme (SC) and D in SCF (DC), 
and low Q in SIF (QI), S in SIF without enzyme (SI) and 
D in SIF (DI) facilitate better film performance. Therefore, 
TS, QC, SC and DC were the high optimization indices. 
QI, SI and DI were the low optimization indices. The best 
film was identified by Equation (5): 
   (Equation 5)
where n represents the line, j represents the array and Rnj 
is the rank of n among the j indices.
SPSS11.5 software was used for all statistical 
analyses. A value of p < 0.05 was considered significant.
RESULTS AND DISCUSSION
Film characteristics
Film appearance and thickness
The gelatin/chitosan films were homogeneous, 
transparent and slightly brittle. The color of the films 
deepened as the chitosan content increased.
The average thicknesses of the films are listed in 
Table II. The thickness of the films significantly increased 
from 0.058 to 0.079 mm when the chitosan content 
increased. The film thickness was likely to be dependent 
on the film nature and composition. This result was similar 
to the resulst reported by Sebti et al. (2007) and Di Pierro 
et al. (2006) who showed possible relationships between 
film thickness and film-forming polymer content and 
nature. 
Tensile strength measurement
The tensile strengths (TS) of the gelatin/chitosan 
films are presented in Table II. The TS of the composite 
membrane increased compared with the chitosan film, and 
the mechanical behavior of the composite film improved 
due to the added gelatin. A few studies have suggested 
that films formed from mixtures likely improved their 
physicochemical properties (Di Pierro et al., 2006; 
Prodpran, Benjakul, Artharn, 2007). Chitosan contains 
more functional groups such as hydroxyls, amines 
and amides, whereas gelatin has more carboxyl and 
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amino groups (Celasco et al., 2008). These groups may 
form electrostatic and hydrogen bonding interactions. 
Furthermore, when the gelatin and chitosan films were 
prepared, the non-covalent interactions, such as hydrogen 
bonding and hydrophobic interactions, likely formed 
between the gelatin and chitosan molecules (Cao, Fu, He, 
2007). Therefore, the tensile strength of the composite 
film increased due to the non-covalent interactions 
between gelatin and chitosan. However, when the chitosan 
content continued to increased up to and beyond a 60% 
mass fraction, the TS of the composite film decreased. 
There may not have been enough gelatin to form the non-
covalent interactions with chitosan.
Influence of the simulated gastrointestinal tract 
environment on the complex film
The swelling behavior, solubility and the in vitro 
degradation of the films are reported in Table III. The 
Q∞ values revealed that all the films had water retention 
capabilities. The Q∞ values of the blended films depended 
on the chitosan/gelatin blend ratios and the physical 
structure of the films. The composite films had improved 
the mechanical strength, thermal stability, and swelling 
capability of films. The Q∞ slightly decreased with the 
chitosan content increasing in SIF and SCF; Q∞ was 
smaller when the chitosan content was 50%-80%. These 
results agreed with studies that reported composite films 
improved mechanical strength (McConnell, Murdan, 
Basit, 2008) and swelling capability of films (Rueda, 
Secall, Bayer, 1999).
The  ab i l i t y  t o  r egu la t e  t he  so lub i l i t y  o f 
biodegradable films presents a number of potential 
advantages in biomaterials. Therefore, the solubility of 
the films at gastrointestinal pH was studied. As shown 
in Table III, the solubility of the blended films in SIF 
and SCF decreased rapidly as the chitosan content 
increased. The solubility of the chitosan film was 14% 
and 18% in SIF and SCF when treated for 24 h at room 
temperature, respectively. It reveals that the blend ratio 
had a significant effect on the solubility of the film. This 
may be because gelatin is a water-soluble polymer and 
because chitosan is insoluble in pure water at neutral pH 
but soluble in acidic solutions.
The films were easy to prepare by casting or spraying 
methods. The properties of the composite films were 
evaluated and these films are experimentally economical 
and statistically efficient (Pinotti et al., 2007). The 
degradation behaviours of the chitosan/gelatin complexes 
were investigated as films. In vitro degradation tests of 
the chitosan/gelatin films were conducted by immersing 
the films in the SGF, SIF and SCF. The effect of chitosan 
content on degradation is presented in Table III. The 
biodegradability of the composite film in SIF rapidly 
decreased with the increasing chitosan content. The 
biodegradability of the blended film in SCF also declined 
when the chitosan content increased, but the trend was 
not obvious when the blended film ratio was 1:1. This 
phenomenon was in line with studies that reported 
that chitosan is susceptible to glycosidic hydrolysis by 
microbial enzymes in the colon (Chourasia, Jain, 2003; 
McConnel, Murdan, Basit, 2008; Vargas et al., 2009).
Results of the RSR Test to Evaluate Preparations 
with Different Compositions
Because all indices were not simply positively 
correlated or negatively correlated, the RSR method was 
applied to evaluate all the films. In Table III, the chitosan/
gelatin/PEG (6:4:1, w/w/w) film was relatively optimal.
Evaluation of the optimal film
FTIR
The changes in the structure of chitosan film were 
examined by FTIR spectroscopy as shown in Figure 2. 
The FTIR spectra of the gelatin, gelatin/chitosan and 
chitosan films showed a broad peak between 2800 and 
3500 cm−1, attributed to the stretching of OH bonds and 
to the hydrogen bridges in films with PEG. The gelatin/
chitosan films had wider peaks in that region, possibly due 
to strong interactions between gelatin and chitosan. This 
result agreed with those reported by Rueda, Secall, and 
TABLE II - Physicochemical properties of the gelatin/chitosan 
films
FN Average thickness 
(mm)
Tensile strength 
(MPa)
1 0.058 29.8
2 0.060 31.2
3 0.061 31.5
4 0.064 33.3
5 0.065 34.9
6 0.067 36.5
7 0.069 33.5
8 0.072 32.5
9 0.073 30.1
10 0.075 23.7
11 0.079 17.4
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Bayer (Mansur, Oréfice, Mansur, 2004) who observed a 
broadened peak around 3400 cm−1.
DSC
To investigate whether each ingredient of the 
complex film interacted with each other, the DSCs of the 
gelatin, chitosan, PEG, gelatin/chitosan/PEG mixture 
and gelatin/chitosan films were performed. As shown 
in Figure 3, the gelatin/chitosan/PEG powder mixture 
had an endothermic transition at approximately 200 °C. 
However, the complex film did not show any endothermic 
or exothermic transition. This result suggested that gelatin 
may have interacted with chitosan or PEG when the film 
was formed. 
SEM
Scanning electron microscopy images of the 
gelatin, chitosan and gelatin/chitosan films are shown 
in Figure 4. It shows that the structure of the gelatin 
film was homogeneous, convex and continuous. The 
chitosan and gelatin/chitosan films were smooth and 
had compact structures, as shown in Figures 4B and 4C. 
These observations agree with reports that the surface 
of chitosan films presents as a smooth, continuous and 
compact structure (Ghaffari et al., 2007; Yu et al., 2011). 
This indicates that the presence of gelatin hardly caused 
structural changes in the chitosan film when the chitosan/
gelatin blend ratio was 6:4.
FIGURE 2 - FTIR spectra of gelatin (A), gelatin/chitosan (B) 
and chitosan (C) films.
TABLE III - Results of the RSR Test
FN
TS(MPa) QI (%) QC (%) SI (%) SC (%) DI (%) DC (%)
RSR
X1 R1 X2 R2 X3 R3 X4 R4 X5 R5 X6 R6 X7 R7
1 29.8 3 - 1 - 1 90 1 91 11 93 1 94 11 0.34
2 31.2 5 - 1 - 1 80 2 86 10 82 2 87 10 0.34
3 31.5 6 272 3 339 11 58 3 83 9 66 3 85 9 0.49
4 33.3 8 204 4 279 10 42 4 70 8 48 4 72 8 0.49
5 34.9 10 176 5 253 9 30 5 36 7 45 5 55 7 0.49
6 36.5 11 102 10 157 6 24 6 25 5 39 7 48 4 0.49
7 33.5 9 100 11 164 7 24 6 29 6 44 6 52 6 0.55
8 32.5 7 114 6 168 8 23 8 24 4 30 9 49 5 0.52
9 30.1 4 104 9 113 3 20 10 21 3 31 8 36 3 0.47
10 23.7 2 107 7 117 4 21 9 19 2 25 10 31 1 0.43
11 17.4 1 105 8 119 5 14 11 18 1 17 11 32 2 0.49
X1–X7 are the values for the TS, QI, QC, SI, SC, DI, and DC, respectively. R1–R7 are the ranks of the TS, QI, QC, SI, SC, DI, and 
DC, respectively.
FIGURE 3 - DSC curves of gelatin/chitosan/PEG mixture (A) 
gelatin/chitosan films (B), chitosan (C), gelatin (D) and PEG (E).
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Biodegradation of the Optimal Film in Rat Colonic 
Medium
The study of the degradation rate of the optimal 
film was conducted by immersing the film samples in rat 
colonic medium. The degradation profile of the optimal 
film is shown in Figure 5. The biodegradability of the 
optimal film in rat colonic medium increased sharply to 
65% after 24 h. Under the same conditions, the degradation 
was only 32% in SCF. A significant difference between 
the weight losses of the optimal film in rat colonic medium 
and in SCF was observed. Rat cecal contents contained 
more enzymes secreted by a variety of bacterial species. 
Chitosan is easily degraded by glycosidic hydrolysis by 
microbial enzymes in the colon (Finegold et al., 1997; 
Gamelin et al., 1998; Yang, 2008). Salyers and Leedle 
(1983) demonstrated that more than one bacterial enzyme 
was involved in the digestion of polysaccharides. Thus, 
the rat bacterial enzymes were more effective in degrading 
chitosan film than pectinase enzyme, promoting the 
degradation of the film by bacterial enzymes.
Attributes of core tablets
The average weight of the uncoated core tablets was 
200 mg. The hardness of the tablets was 4.6 kg/cm2, and 
their friability ranged from 0.08% to 0.20% (w/w). The 
uncoated tablets were prepared using 1% PVPP (w/w).
In vitro drug release studies in simulated 
gastrointestinal fluids
The in vitro release studies were performed in 
medium at different pHs at 37 ºC ± 0.5 ºC. As was shown in 
Figure 6A, the uncoated and gelatin/chitosan-coated tablets 
showed immediate release characteristics in SGF, compared 
with the Eudragit and bilayer-coated tablets. However, the 
Eudragit coating prevented drug release in SGF at pH 1.2 
but allowed for rapid and complete drug release in SIF when 
the pH was raised to pH 7.4. There was no measurable drug 
release for bilayer-coated tablets up to 2 h in SGF (pH 1.2). 
In SIF at pH 7.4, the drug release was negligible (< 5%) up 
to 4 h. Thus, the bilayer coating prevented drug release in 
SGF and SIF. After dissolution, the bilayer-coated tablet 
was tested in SGF for 2 h and SIF for 4 h, and its dissolution 
was further detected in SCF. The drug release in the bilayer-
coated tablet in SCF increased over time, and the drug 
was almost completely released after 24 h (Figure 6B). 
Therefore, the Eudragit and chitosan/gelatin-coated tablets 
would likely resist release in the upper GI tract and thereby, 
prevent drug release at non-targeted sites.
Stability studies 
Accelerated stability studies were carried out for 
a duration of 6 months as per ICH guidelines. As shown 
in Table IV, the formulation was stable according to the 
evaluation of the formulation for physical appearance, 
drug content and drug release profile.
FIGURE 4 - SEM images of the surfaces of gelatin (A); chitosan (B) and gelatin/chitosan (C) films.
FIGURE 5 - Biodegradation of the optimal film in SCF and 
RCM.
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CONCLUSION
We have designed a new microbially triggered 
system based on chitosan for colonic drug delivery. The 
characteristics of the designed complex film depend on 
the chitosan/gelatin blend ratio; a 6:4 blend ratio was 
optimal. The Eudragit and chitosan/gelatin bilayer coating 
system prevented drug release in SGF and SIF. The drug 
was almost completely released in SCF after 24 h. Colon-
targeted drug delivery was achieved by using a chitosan/
gelatin complex film and a multilayer coating system.
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